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In this issue of the journal, Gorzelniak et al. [1]
examined the expression of the genes coding for the
components of the renin–angiotensin system (RAS) in
the subcutaneous abdominal adipocytes of 30 women,
of whom 18 were obese and 10 had hypertension in
combination with obesity. Compared with 12 lean
women, the expression of the angiotensinogen (AGT)
gene was significantly lower in the adipocytes from the
18 obese subjects. Furthermore, the renin, angiotensin
II-converting enzyme and angiotensin II type-1 recep-
tor (ATR1) genes were up-regulated in the adipocytes
of 10 obese hypertensive women. Thus, Gorzelniak et
al. [1] demonstrated that the RAS genes are differently
expressed in adipocytes of obese and hypertensive
women. Using an innovative approach, these investiga-
tors completed their clinical study with in-vitro experi-
ments. They observed that hydrocortisone increased
ATR1 gene expression in human adipocytes in a time-
and dose-dependent manner, whereas hydrocortisone
did not influence the expression of the other RAS
genes. Furthermore, insulin, 17â-oestradiol, triiodo-L-
thyronine and angiotensin II did not influence any of
the RAS genes in the in-vitro experiments. The work
of Gorzelniak et al. [1] is an important contribution to
the existing literature, but should also be interpreted
within the context of certain limitations. Although the
sample size was larger than in many other reports, the
Berlin group only recruited women. Furthermore, dif-
ferences in age and menstrual cycle may have impacted
on the findings and the study did not include lean
hypertensive women.
The RAS has long been recognized as an important
regulator of systemic blood pressure, renal electrolyte
homeostasis, brain function and vascular growth. Com-
ponents of the RAS are present in a variety of tissues,
such as the kidney, adrenal gland, brain, heart and
arterial wall [2–4]. Over the past decade, evidence has
accumulated demonstrating that in many organs this
locally expressed RAS behaves as an autocrine and/or
paracrine regulatory system [5,6]. More recently, in line
with the findings of Gorzelniak et al. [1], several authors
reported that some RAS components are locally pro-
duced in adipose tissue [7–10]. These findings gave
rise to the hypothesis that the intra-adipocyte RAS
system might play an important pathogenetic role in
the development of human obesity and associated
chronic disorders, such as hypertension. However, the
functional significance of the local RAS in adipocytes
remains to be clarified.
Angiotensin II, produced by conversion of AGT by the
local RAS of adipocytes, participates in the control of
the growth and differentiation of fat tissue [11] and in
the regulation of adipogenesis and lipid metabolism
[12]. Recently, Van Harmelen et al. [13] demonstrated
that, in subcutaneous adipose tissue from obese men,
AGT mRNA expression was twice as high as in non-
obese controls. In addition, these authors found a posi-
tive correlation between body mass index and local
AGT mRNA expression in subcutaneous adipose tis-
sue. They suggested that, in men, AGT locally pro-
duced by adipocytes might contribute to the
development of upper body obesity. Gorzelniak et al.
[1] reported a lower AGT expression in subcutaneous
adipocytes of obese women. Initially, the respective
findings of Van Harmelen et al. and Gorzelniak et al.
may appear to be contradictory. However, in young and
middle-aged subjects, there exists pronounced sexual
dimorphism in body fat distribution, with predomi-
nantly central fat accumulation in men and more
peripheral fat deposition in women. The amount of
visceral fat augments with age in both genders and this
increase is present in lean, overweight and obese
subjects [14]. Furthermore, after menopause, there is a
redistribution of fat tissue from peripheral and abdom-
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inal subcutaneous depots to abdominal visceral sites
with a shift from the gynoid towards the android
phenotype [14,15]. Several investigators found, in lean
as well as obese subjects, that AGT mRNA expression
is 30% [16] to 100% [17] higher in omental than
subcutaneous fat tissue. The obese women in the study
by Gorzelniak et al. were predominantly (72.2%) post-
menopausal, and subcutaneous rather than omental
tissue was investigated in the clinical part of the study.
For the in-vitro experiments, Gorzelniak et al. used fat
tissue removed from women undergoing breast reduc-
tion surgery. Thus, the site of fat tissue sampling might
possibly explain the divergent or apparently contra-
dictory results. In future experiments, the tissue from
which adipocytes are harvested should be better stan-
dardized according to sex, menopausal status and age,
and defined a priori in function of the specific hypoth-
esis to be tested. In contrast to the findings of
Gorzelniak et al., Giacchetti et al. [17] found lower
AGT mRNA expression in the subcutaneous fat tissue
of obese subjects if they were hypertensive rather than
normotensive. However, these authors did not specify
the gender and age of their participants, which makes
interpretation of their results difficult.
In the study by Gorzelniak et al. [1], the plasma
concentration of AGT was similar irrespective of blood
pressure and body weight. Nonetheless, AGT and
variation in its gene have been implicated in the
pathogenesis of hypertension and obesity. Jeunemaıˆtre
et al. [18] were among the first to show that the T-allele
of the AGT M235T polymorphism was significantly
associated with increased circulating AGT and hyper-
tension. The M235T polymorphism is in linkage
disequilibrium with a threonine-to-methionine substi-
tution at amino acid 174 (T174M) [19] and with the two
other polymorphisms in the core promoter area of the
gene (G-6A and A-20C) [19,20]. Recent research re-
vealed that the ÿ6A variant is associated with elevated
AGT gene transcription, increased AGT gene expres-
sion, elevated plasma AGT levels and hypertension
[21–23]. The ÿ20C allele is also correlated with
enhanced AGT transcription in vitro [24] as well as
higher plasma AGT and increased blood pressure in
humans [19,20]. Furthermore, several studies noticed
an association between obesity-related phenotypes and
various polymorphisms in the AGT gene. Ishigami et al.
[25] reported a positive correlation between the ÿ20C
mutation, plasma AGT levels and percentage body fat.
Rankinen et al. [26] demonstrated that the M235T
polymorphism is associated with body fatness in wo-
men. Hegele et al. [27] found that, in men, the AGT
174M allele was associated with a significantly higher
systolic blood pressure but a lower waist-to-hip ratio. As
blood pressure and obesity are interdependent pheno-
types, the role of AGT and polymorphism in its gene
must be further clarified. An important issue to be
addressed is whether genetic polymorphisms in the
AGT gene not only influence circulating AGT levels,
but also those in adipocytes or other cells.
In line with previous animal studies [28], Gorzelniak et
al. [1] observed enhanced ATR1 mRNA expression in
the adipocytes of obese hypertensive women. Further-
more, their in-vitro experiments showed that ATR1
expression increased after incubation with hydrocorti-
sone. Various hormones, including circulating oestro-
gens, triiodo-L-thyronine and angiotensin II, promote
AGT synthesis in human hepatocytes [29]. To date,
few studies in humans addressed the issue of the local
regulation of the intra-adipocyte RAS [30]. In experi-
mental animals, only glucocorticoids and insulin were
shown to be the hormones that in some, but not all,
studies modulated AGT expression in adipocytes
[31,32].
As expected, the authors found that obesity is asso-
ciated with higher serum concentration of leptin. This
hormone, secreted by fat cells in proportion to body fat
stores, is involved in energy balance regulation by
inhibiting lipogenesis, stimulating lipolysis and acting
on the brain to inhibit feeding [33]. With regard to
blood pressure homeostasis, leptin appears to have
divergent effects. A pressor response is attributable to
sympathetic activation and a depressor action to nitric
oxide release and an increase in the renal sodium and
water excretion [34]. Although leptin possesses both
depressor and pressor actions, its chronic effects appear
to be predominantly pressor. The relationship between
excess adiposity and blood pressure has long been
recognized. In epidemiological studies in the developed
world [35], as well as in developing countries [36], body
mass index explains up to one-third of the overall blood
pressure variability. Leptin may be involved, but cer-
tainly other nervous, humoral and/or genetic mechan-
isms may be key factors in causing the association
between hypertension and obesity, or in enhancing the
susceptibility of human subjects to become both hyper-
tensive and obese.
The demonstration of a functional RAS within adipo-
cytes and the role of leptin should change our way of
thinking about adipose tissue. It should no longer be
regarded as a passive depot for storing excess energy in
the form of triglycerides, but as a true endocrine organ,
which actively regulates pathways responsible for en-
ergy balance and fat metabolism. Adipocytes also
participate in vascular function and blood pressure
control through the secretion of chemical messengers,
where activity is controlled by a complex network of
hormonal and neuronal signals [6,37].
In conclusion, the role of the local RAS system in
adipocytes in the pathogenesis of obesity and chronic
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diseases, such as hypertension and diabetes mellitus,
remains to be clarified in men as well as in women.
The innovative approach of Gorzelniak et al., combin-
ing a clinical study with in-vitro experiments, merits to
serve as a model for further research. Future studies
should account for possible differences attributable to
gender, menopausal status, age, underlying diseases
and genetic polymorphisms.
References
1 Gorzelniak K, Engeli S, Jurgen J, Luft FC, Sharma AM. Hormonal
regulation of the human adipose-tissue renin–angiotensin system: rela-
tionship to obesity and hypertension. J Hypertens 2002; 20:965–973.
2 Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular
biology of the tissue renin–angiotensin systems. Regul Pept 1993; 43:
1–20.
3 Unger T, Gohlke P. Tissue renin–angiotensin systems in the heart and
vasculature: possible involvement in the cardiovascular actions of convert-
ing enzyme inhibitors Am Heart J 1990; 65:31–101.
4 Dzau VJ. Circulating versus local RAS in cardiovascular homeostasis
Circulation 1988; 77 (suppl I):4–13.
5 Dzau VJ. Implications of local angiotensin production in cardiovascular
physiology and pharmacology. Am J Cardiol 1987; 59:59A–65A.
6 Ailhaud G. Adipose tissue as an endocrine organ. Int J Obesity 2000;
24 (suppl 2):S1–S3.
7 Schling P, Mallow H, Trindl A, Lo¨ffler G. Evidence for a local renin–
angiotensin system in primary cultured human preadipocytes. Int J
Obesity 1999; 23:336–341.
8 Jonsson JR, Game PA, Head RJ, Frewin DB. The expression and
localization of the angiotensin-converting enzyme mRNA in human
adipose tissue. Blood Press 1994; 3:72–75.
9 Jones BH, Standridge MK, Taylor JW, Moustaid N. Angiotensinogen gene
expression in adipose tissue: analysis of obese models and hormonal and
nutritional control. Am J Physiol 1997; 273:R236–R242.
10 Karlsson C, Lindell K, Ottosson M, Sjo¨stro¨m L, Carlsson B, Carlsson
LMS. Human adipose tissue expresses angiotensinogen and enzymes
required for its conversion to angiotensin II. J Clin Endocrinol Metab
1998; 83:3925–3929.
11 Morgan L, Pipkin FB, Kalsheker N. Angiotensinogen: molecular biology,
biochemistry and physiology. Int J Biochem Cell Biol 1996; 28:
1211–1222.
12 Jones BH, Standridge MK, Taylor JW, Moustaid N. Angiotensin II
increases lipogenesis in 3T3-L1 and human adipose cells. Endocrin-
ology 1997; 138:1512–1519.
13 Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner
P. Increased adipose angiotensinogen gene expression in human obesity.
Obesity Res 2000; 8:337–341.
14 Enzi G, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F.
Subcutaneous and visceral fat distribution according to sex, age and
overweight, evaluated by computed tomography. Am J Clin Nutr 1986;
44:739–746.
15 Zamboni M, Armellini F, Milani MP, De Marchi M, Todesco T, Robbi R,
et al. Body fat distribution in pre- and post-menopausal women: metabolic
and anthropometric variables and their inter-relationships. Int J Obes
Relat Metab Disord 1992; 16:495–504.
16 Van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdot-
tir S, Hoffstedt J, et al. The association of human adipose angiotensino-
gen gene expression with abdominal fat distribution in obesity. Int J Obes
Relat Metab Disord 2000; 24:673–678.
17 Giacchetti G, Faloia E, Sardu C, Camilloni MA, Mariniello B, Gatti C,
et al. Gene expression of angiotensinogen in adipose tissue of obese
patients. Int J Obes Relat Metab Disord 2000; 24 (suppl 2):
S142–S143.
18 Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS,
Charru A, et al. Molecular basis of human hypertension: role of angioten-
sinogen. Cell 1992; 71:169–180.
19 Jeunemaitre X, Inoue I, William C, Charru A, Tichet J, Powers M, et al.
Haplotypes of angiotensinogen in essential hypertension. Am J Hum
Genet 1997; 60:1448–1460.
20 Ishigami T, Umemura S, Tamura K, Hibi K, Nyui N, Kihara M, et al.
Essential hypertension and 59 upstream core promoter region of human
angiotensinogen gene. Hypertension 1997; 30:1325–1330.
21 Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M,
et al. A nucleotide substitution in the promoter of human angiotensinogen
is associated with essential hypertension and affects basal transcription
in vitro. J Clin Invest 1997; 99:1786–1797.
22 Hunt SC, Cook NR, Oberman A, Cutler JA, Hennekens CH, Allender PS,
et al. Angiotensinogen genotype, sodium reduction, weight loss, and the
prevention of hypertension. Trials of hypertension prevention, phase II.
Hypertension 1998; 32:393–401.
23 Morgan T, Craven C, Ward K. Human spiral artery renin–angiotensin
system. Hypertension 1998; 32:683–687.
24 Zhao YY, Zhou J, Narayanan CS, Cui Y, Kumar A. Role of C/A
polymorphism at ÿ20 on the expression of human angiotensinogen gene.
Hypertension 1999; 33:108–115.
25 Ishigami T, Tamura K, Fujita T, Kobayashi I, Hibi K, Kihara M, et al.
Angiotensinogen gene polymorphism near transcription start site and
blood pressure. Role of a T-to-C transition at intron I. Hypertension 1999;
34:430–434.
26 Rankinen T, Gagnon J, Perusse L, Rice T, Leon AS, Skinner JS, et al.
Body fat, resting and exercise blood pressure and the angiotensinogen
M235T polymorphism: the heritage family study. Obes Res 1999;
7:423–430.
27 Hegele RA, Brunt JH, Connelly PW. Genetic variation on chromosome 1
associated with variation in body fat distribution in men. Circulation
1995; 92:1089–1093.
28 Giacchetti G, Sechi LA, Griffin CA, Don BR, Mantero F, Schambelan M.
The tissue renin–angiotensin system in rats with fructose-induced hyper-
tension: overexpression of type 1 angiotensin II receptor in adipose
tissue. J Hypertens 2000; 18:695–702.
29 Clauser E, Gaillard I, Wei L, Corvol P. Regulation of the angiotensinogen
gene. Am J Hypertens 1989; 2:403–410.
30 Schling P, Loffer G. Effects of angiotensin II on adipose conversion and
expression of genes of the renin–angiotensin system in human preadipo-
cytes. Horm Metab Res 2001; 33:189–195.
31 Aubert J, Darimont C, Safonova I, Ailhaud G, Negrel R. Regulation by
glucocorticoids of angiotensinogen gene expression and secretion in
adipose cells Biochem J 1997; 328:701–706.
32 Aubert J, Safonova I, Negrel R, Ailhaud G. Insulin down-regulates
angiotensinogen gene expression and angiotensinogen secretion in
cultured adipose cells. Biochem Biophys Res Commun 1998; 250:
77–82.
33 Fru¨hbeck G, Jebb SA, Prentice AM. Leptin: physiology and pathophysiol-
ogy. Clin Physiol 1998; 18:399–419.
34 Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG. Obesity-
induced hypertension. New concepts from the emerging biology of
obesity. Hypertension 1999; 33:537–541.
35 M’Buyamba-Kabangu JR, Fagard R, Lijnen P, Mbuy wa Mbuy R, Staessen
J, et al. Blood pressure and urinary cations in urban Bantu of Zaire. Am J
Epidemiol 1986; 124:957–968.
36 Staessen J, Bulpitt C, Fagard R, Joossens JV, Lijnen P, Amery A. Four
urinary cations and blood pressure: a population study in two Belgian
towns. Am J Epidemiol 1983; 117:676–687.
37 Shuldiner AR, Yang R, Gong DW. Resistin, obesity, and insulin resis-
tance – the emerging role of the adipocyte as an endocrine organ N Engl
J Med 2001; 345:1345–1346.
Hormonal regulation of human adipocytes Tikhonoff and Staessen 841
